If you’ve seen recent headlines promising a cure for hair loss, chances are they were about JAK inhibitors. These medicines have transformed the outlook for one form of hair loss, and the latest trial results are the most striking yet. However, there’s a catch. The condition they treat is alopecia areata, an autoimmune disease and not the androgenetic (pattern) hair loss that most men and women have. In this article, we review what JAK inhibitors are and how well they treat hair loss. We’ll also explore who can get them in the UK and what the options are for common male and female pattern baldness.
What are JAK Inhibitors?
JAK inhibitors are a group of medicines that calm down overactive immune signalling. The name comes from Janus kinases, a family of enzymes that sit just inside immune cells and pass on chemical messages through a pathway called JAK-STAT. You can think of this pathway a bit like an office intercom. When inflammatory messages arrive at the surface of a cell, the JAK enzymes relay them inwards and the cell acts on the instruction. In autoimmune diseases, that intercom never stops ringing. JAK inhibitors work by muffling it, which reduces the inflammation driving the disease.
Researchers first developed these drugs for inflammatory conditions like rheumatoid arthritis, and they quickly gained ground across medicine. Doctors now prescribe JAK inhibitors such as baricitinib and upadacitinib for arthritis, eczema and inflammatory bowel disease. Their arrival in hair medicine is more recent. It follows the discovery that the same signalling pathway they block also drives the immune attack behind alopecia areata.
How Do JAK Inhibitors Treat Hair Loss?
JAK inhibitors treat hair loss caused by alopecia areata, an autoimmune condition estimated to affect around 2% of people. Normally, your immune system leaves hair follicles alone. In fact, follicles are one of the few sites in the body with a special protection known as immune privilege. This acts as a kind of ‘do not disturb’ sign for immune cells. In alopecia areata, this protection breaks down. Immune cells mistake the follicle for a threat and attack it, which forces the hair out and blocks regrowth. The result is the sudden, patchy hair loss the condition is known for. It can progress to loss of all scalp or even body hair, including eyebrows, eyelashes and beard hair.
The attack itself runs on the JAK-STAT pathway. Inflammatory messengers such as interferon-gamma and interleukin-15 pass their instructions through JAK enzymes, and each round of signalling recruits more immune cells to the follicle. JAK inhibitors interrupt this relay. This means the inflammatory messages stop getting through, the attack quietens down and the follicle can wake up and grow hair again. Crucially, the follicles in alopecia areata are dormant rather than destroyed, so there’s something left to rescue. This is also why JAK inhibitors don’t help scarring alopecia, where the follicle has been damaged and permanently replaced by scar tissue.
How Well Do JAK Inhibitors Work for Alopecia Areata?
For severe alopecia areata, JAK inhibitors are the best-evidenced treatment we have. The first to prove itself was baricitinib. In two phase 3 trials of adults who had lost at least half their scalp hair, 38.8% and 35.9% of patients on the higher dose regrew hair to at least 80% scalp coverage by 36 weeks. This was against roughly 3 to 6% on placebo. By one year, around 2 in 5 patients on that dose had reached the same milestone. Ritlecitinib followed with similar results in patients as young as 12. In its pivotal trial, 23% of patients reached the 80% coverage mark by 24 weeks. This rose to 43% by 48 weeks. Interestingly, some patients needed over a year of treatment before responding, so regrowth is very much a slow burn. A third drug, deuruxolitinib, helped about 1 in 3 patients reach the same target within 24 weeks.
The newest results belong to upadacitinib, and they are the reason for the current wave of headlines. In two phase 3 trials of 1,400 adults and adolescents published in August 2026, 45% of patients on the lower dose and 55% on the higher regrew at least 80% of hair within 24 weeks. This was in comparison to under 4% on placebo. Eyebrow and eyelash regrowth improved too. These are the strongest response rates for any alopecia areata treatment so far. Because upadacitinib is already a familiar NHS medicine for arthritis and eczema, the press coverage has been glowing.
However, none of these medicines works for everyone, and even in the strongest trial results so far, almost half of patients didn’t reach the target. It also helps to remember that JAK inhibitors control alopecia areata rather than cure it. The immune attack resumes once the signal blockade lifts. In fact, a meta-analysis found that around half of patients relapsed usually after stopping treatment. So, for most people, keeping the regrowth means staying on the medicine.
Do JAK Inhibitors Work for Male & Female Pattern Hair Loss?
There is currently no reliable evidence that JAK inhibitors treat male or female pattern hair loss. This matters because pattern hair loss, also called androgenetic alopecia, is by far the most common type. However, it’s a completely different disease. Whilst alopecia areata is an immune attack on healthy follicles, pattern hair loss is due to the hormone DHT, which gradually shrinks genetically sensitive follicles in a process called follicular miniaturisation. There’s no rogue immune signal for a JAK inhibitor to block, so the mechanism doesn’t apply. It’s like taking an antibiotic for a viral infection.
This is the distinction the ‘cure for baldness’ headlines tend to blur. Alopecia areata affects an estimated 400,000 people in the UK, whereas pattern hair loss affects millions, so most people reading those stories have the condition JAK inhibitors don’t treat. Luckily, pattern hair loss is far from untreatable. Minoxidil, finasteride, dutasteride and spironolactone all have decades of evidence behind them, and they remain the treatments that actually address the hormonal biology of balding.
What are the Side Effects & Risks of JAK Inhibitors?
JAK inhibitors are serious medicines, and their risks deserve the same attention as their results. The common side effects in the alopecia areata trials were mostly manageable, including upper respiratory infections, headaches, acne and raised muscle enzyme levels on blood tests. The bigger issue is the rarer risks that come with dampening immune signalling across the whole body. In 2023, the MHRA issued safety measures for the whole class after evidence of increased risks of major cardiovascular events, blood clots, some cancers and serious infections. As such, UK guidance says these drugs should be avoided in people over 65, current or long-term past smokers and those with cardiovascular or cancer risk factors unless there is no suitable alternative.
This is why JAK inhibitors for hair loss are specialist medicines rather than something a GP prescribes on a first visit. Before starting, patients are screened for infections like tuberculosis and hepatitis, and treatment involves ongoing blood tests and periodic skin checks. None of this makes them bad drugs. It does mean the decision to take one requires a proper medical assessment, weighing severe hair loss and its real psychological toll against systemic risks.
Can You Get JAK Inhibitors for Hair Loss in the UK?
Yes, but only for severe alopecia areata and only through a dermatologist. The clearest route is ritlecitinib (brand name Litfulo), which is licensed for people aged 12 and over. In 2024, it became the first alopecia areata treatment recommended on the NHS, with NICE estimating it could help up to 14,000 people in England, and it is now available across all four UK nations. If your hair loss is patchy or sudden, the path starts with your GP, who can refer you to an NHS dermatology clinic to confirm the diagnosis and assess whether you meet the NICE criteria for treatment.
The picture for the other three is more mixed. Baricitinib (Olumiant) is licensed in the UK for adults with severe alopecia areata, but NICE did not recommend it for routine NHS use. So, in practice, it is prescribed privately by consultant dermatologists. Deuruxolitinib (Leqselvi) received its UK licence in 2026 and is awaiting a NICE decision on NHS funding. Upadacitinib (Rinvoq), the drug behind this summer’s coverage, was approved in the EU for severe alopecia areata in July 2026 but, at the time of writing, is not yet licensed for this condition in the UK. Here it remains an unlicensed, off-label option for alopecia areata that only a specialist would consider. Whatever the route, please steer clear of any website offering to sell you JAK inhibitors directly. These are prescription-only medicines with real risks, and they need proper screening and monitoring.
| JAK inhibitor | UK status for alopecia areata | What the evidence shows |
|---|---|---|
| Ritlecitinib (Litfulo) | Licensed for ages 12+. Recommended by NICE and available on the NHS | 23% regrew to 80% scalp coverage by 24 weeks, 43% by 48 weeks |
| Baricitinib (Olumiant) | Licensed for adults but not recommended by NICE, so mainly private | Around 2 in 5 on the higher dose regrew to 80% coverage within a year |
| Deuruxolitinib (Leqselvi) | Licensed for adults in 2026, awaiting a NICE decision | About 1 in 3 regrew to 80% coverage by 24 weeks |
| Upadacitinib (Rinvoq) | Not yet licensed for alopecia areata in the UK. EU approved July 2026 | 45 to 55% regrew to 80% coverage by 24 weeks, the strongest results so far |
JAK inhibitors are a rare example of a hair loss treatment that has lived up to the hype. For severe alopecia areata, they have turned a disease with no reliable options into one where the newest drug helps around half of patients regrow most of their hair. However, they are not a cure and carry serious risks that demand specialist care. So, if your hair loss is sudden or patchy, see your GP and ask about a dermatology referral. Whilst JAK inhibitors do nothing for the pattern hair loss most people have, there are a number of established hair loss treatments. There’s also a growing area of research into treatments specifically targeting androgenetic hair loss with promising experimental molecules like PP405, Breezula and deoxyribose sugar under review.
At City Skin Clinic, we understand that hair loss is a deeply personal journey. We’re an online clinic offering topical prescription treatments only, so we don’t prescribe JAK inhibitors or any oral medication. Severe alopecia areata needs care from a consultant dermatologist via your GP. For pattern hair loss, however, our doctors can create personalised topical treatments for women and men using actives like minoxidil, finasteride, dutasteride and spironolactone where appropriate. To start your plan, book a virtual video consultation or use our online consultation form. The journey towards great skin and hair starts here.
This article is intended for general informational purposes only and is not a substitute for medical advice, diagnosis or treatment. Always consult a qualified medical provider for any medical concerns or questions you might have.
